The DEA and opponents have filed new briefs in the federal cannabis rescheduling hearing, shaping the future of marijuana policy and delivery laws nationwide.

Georgia, Vermont and California officials say DEA has offered little implementation guidance after marijuana moved to Schedule III for state medical programs, leaving labeling, taxes and inspections unclear.

A new DEA registration pathway pulls state-licensed medical cannabis manufacturers, distributors, and labs into the federal Schedule III framework—potentially easing 280E tax pain.

DEA adds dedicated federal registration paths for state-licensed medical marijuana manufacturers, distributors, and testing labs, expanding beyond dispensaries amid ongoing Schedule III transition.

A new op-ed spotlights how Latino and immigrant workers power cannabis cultivation and retail—and why federal immigration policy and partial rescheduling still put them at risk.

Anti-marijuana groups and a pharma company asked a D.C. appeals court to revive their challenge to a Medicare initiative that lets providers furnish certain hemp-derived CBD products to beneficiaries.

DEA’s 2026 Drugs of Abuse update says no deaths from marijuana overdose and reflects federal moves toward Schedule III for certain cannabis products. Here’s what it means in practice.

A landmark Phase 2 study will test smoked, high-THC flower versus placebo in 320 veteran participants with moderate to severe PTSD. Here’s what’s being studied and why it matters for DMV patients.

A DEA administrative law judge halted the federal rescheduling proceeding to weigh a new GAO report on agency procedures—delaying a final ruling and keeping the status quo in place for now.

Congress’s PATH Caucus outlines a federal–state roadmap to integrate psychedelic-assisted therapy into U.S. care with clinical safeguards, data tracking and provider standards.

Rescheduling momentum is real, but tax experts say cannabis businesses may remain under 280E for the entire 2025 tax year. Here’s what that means for DMV operators and delivery services.

A DEA administrative law judge issued a stay on the wider adult-use rescheduling review, weighing a GAO report’s admission and extra briefing. The pause does not alter April’s medical marijuana move to Schedule III, per mg Magazine.

A DEA administrative judge granted opponents’ request to pause the federal marijuana rescheduling hearing so a GAO report on scheduling “gaps” can be entered. Here’s what that means in practice for DC, Maryland and Virginia.

A DEA administrative judge paused the cannabis rescheduling hearing to consider a GAO watchdog report on process gaps. A DEA response is due by October 13, adding delay and uncertainty.

A quiet clause in last year’s federal budget could put the DEA in charge of hemp seeds this November—disrupting farms, research, and small seed businesses nationwide.

Marijuana Moment reports a Texas Senate candidate’s alcohol-linked cash haul while opposing cannabis reform—plus new research on teen use and clinical science DMVers should track.

DEA released the marijuana rescheduling hearing transcript as ALJ Derek Julius weighs a Schedule III recommendation. Here’s what it could mean for DMV delivery compliance.

State regulators say DEA guidance is essential to align medical cannabis rules with the new Schedule III status—especially for delivery, labeling, and patient access across the DMV.

A new GAO report says DEA and FDA lack clear drug-scheduling procedures just as an ALJ reviews moving cannabis to Schedule III and court fights continue.

A little-known 1969 cannabis journal argued the core points the DEA just made on rescheduling—raising new stakes for patients, researchers, and the DMV in 2026.